Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...

Array Bridge is testing promising drug candidates that can effectively bind and even degrade target proteins, but not via their active sites.

Why ALZpath, GeneDX, 10x Genomics, Protagonist Therapeutics, and Recursion are among the most innovative biotech companies of 2025.

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Notably, the researchers succeeded in bio-orthogonal labeling of two key cancer biomarker ... It could pave the way for next-generation antibody-drug conjugates (ADCs) targeting specific cancer ...

Shanghai scientists have made breakthrough in protein design by leveraging artificial intelligence, establishing the world's largest protein sequence dataset and designing models based on this dataset ...

Scientists in Shanghai have made a breakthrough in protein design by leveraging artificial intelligence, establishing the ...

Bio-conjugation techniques utilizing proteins, such as attaching fluorescent markers to identify cancer cells, are actively advancing disease diagnosis and drug development research. However, existing ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Q4 2024 Earnings Call Transcript March 31, 2025 Omeros Corporation beats earnings expectations. Reported EPS is $-0.54, ...

The FDA approved Lilly’s Alzheimer’s drug, Kisunla, a monoclonal antibody ... with the enzyme inhibitor miglustat, which has long been used as the primary, albeit off-label, treatment for ...